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Abstract
Magnetic drug delivery refers to the physical confinement of therapeutic magnetic nanoparticles to
regions of disease, tumors, infections and blood clots. Predicting the effectiveness of magnetic
focusing in vivo is critical for the design and use of magnetic drug delivery systems. However,
current simple back-of-the-envelope estimates have proven insufficient for this task. In this article,
we present an analysis of nanoparticle distribution, in and around a single blood vessel (a Krogh
tissue cylinder), located at any depth in the body, with any physiologically relevant blood flow
velocity, diffusion and extravasation properties, and with any applied magnetic force on the
particles. For any such blood vessel our analysis predicts one of three distinct types of particle
behavior (velocity dominated, magnetic dominated or boundary-layer formation), which can be
uniquely determined by looking up the values of three nondimensional numbers we define. We
compare our predictions to previously published magnetic-focusing in vitro and in vivo studies.
Not only do we find agreement between our predictions and prior observations, but we are also
able to quantitatively explain behavior that was not understood previously.
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In magnetic drug targeting, magnetic particles containing or coated with therapeutics are
concentrated to sites of disease by applied magnetic fields. This has allowed focusing of
chemotherapy to solid tumors in Phase I human clinical trials [1], and in animal experiments
[2-5], and is being used to target drugs to other types of disease locations (e.g., to regions of
thrombosis [6]). During such treatments, magnetic particles are usually injected into the
bloodstream, and magnets are then used to concentrate them to target locations. There is a
need to know which locations can or cannot be effectively reached by magnetic drug
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targeting. Key issues include whether the applied magnetic forces can hold particles against
blood flow, at which body depth, in which blood vessels, and how far particles subsequently
travel from the vessels into surrounding tissue.
Physical parameters, such as particle size and materials, as well as magnet placement, size,
shape and strength, are crucial for the success of magnetic drug focusing. However, there is
little ability to predict how these parameters will affect particle behavior in vivo. This has
forced critical magnetic drug delivery design choices to be made based on intuition,
empirical data and simple engineering estimates – and these rough tools are proving
insufficient. For example, the question of whether magnets can or cannot hold nanoparticles
against blood flow is often addressed when designing experiments by comparing the
maximum force that the blood flow exerts on a particle against the applied magnetic force.
This analysis underpredicts the ability of a magnetic field to hold particles against blood
flow, and does not match behavior observed in animal experiments. In rats, the slowest
blood flow velocity, in capillaries, has been measured to be approxiately 0.1 mm/s [7], a
velocity that will create a (Stokes) drag force [8] of Fblood ≈ 7 × 10−13 Newtons on a 250 nm
diameter particle at the vessel center. For the rat experiments shown in Figure 1, a 0.5 Tesla,
5 cm long, 5 mm wide permanent magnet was used to concentrate 250 nm diameter iron
oxide nanoparticles underneath the skin against blood flow. The magnetic field created by
this magnet, and the resulting magnetic force [8], works out to be only Fmag ≈ 1 × 10−13
Newtons, a factor of a seventh smaller. This calculation suggests that blood flow forces will
overcome the applied magnetic forces; yet, magnetic drug focusing was clearly observed, as
shown in Figure 1. This experiment was repeated for 100 nm particles, in which case the
magnetic force is 109 times smaller than the vessel centerline blood drag force, yet focusing
remained successful.
Methods
As shown in Figure 2B, we focus our attention on nanoparticle behavior in and around a
single blood vessel (a Krogh tissue cylinder geometry [9]). This blood vessel can be of any
type, from a major artery or a vein, to a minor capillary, fenestrated or not, at any depth, and
any applied magnetic force can be considered. Instead of using simple engineering
estimates, starting from physical first principles, we state and then solve the equations
governing the diffusion, convection and magnetic transport of nanoparticles in the blood and
into surrounding tissue. These equations describe the time progression of the nanoparticle
concentration at every spatial location in the blood and surrounding tissue. The first equation
captures particle transport due to convection by blood flow, particle diffusion (including
particle scattering by collisions with blood cells [10]), and particle motion due to magnetic
forces (see [11] for details).
(1)
Here, CB is the concentration of particles at each location in the blood,  is the blood
velocity, t is time, ▽ is the gradient operator, and Pe and Ψ are the Péclet and magnetic-
Richardson numbers. The next two equations include diffusion and transport in the
endothelial membrane and surrounding tissue. This type of formulation is standard, and, as
in [9], extravasation (or lack thereof) is modeled by adjusting the diffusion coefficient in the
endothelium, D, to a nonzero (or zero) value. Additional tissue-specific properties, for
example, decreased resistance to nanoparticle motion owing to a compromised extracellular
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matrix with larger interstitial spaces in a tumor region, can be accounted for by decreasing
the magnetic drift coefficient (the magnetic-Richardson number), Ψ, in that region.
Increased interstitial tumor pressure can decrease blood flow velocity into a tumor and,
therefore, is reflected by choosing an appropriately lower VBmax velocity in affected blood
vessels.
(2)
CM and CT are the concentrations of particles at every location in the endothelial membrane
and tissue, and D and DT are the endothelium and tissue Renkin-reduced diffusion
coefficients. As shown in Figure 2B, it is assumed that the blood vessel is aligned
perpendicularly to the applied magnetic force. If the vessel is at an angle to the magnetic
force, then only the perpendicular part of the force should be used for FM below, and the
tangential part can be added to the drag forces along the blood vessel, to FS. These equations
are stated in nondimensional variables, meaning the variables used have been chosen to
highlight the competition between phenomena: between blood drag and magnetic forces,
and between diffusion in the blood and surrounding tissue. This nondimensional scaling
reveals the key numbers Ψ, D, DT and Pe, which uniquely determine particle behavior [11].
Specifically, the magnetic-Richardson number, Ψ, quantifies the ratio between the applied
magnetic forces and the maximum drag forces that the blood in that vessel can exert on the
nanoparticles. We define it as the ratio:
(3)
The magnetic force depends both on the magnetic field  (units: A/m) created by the
magnet and its spatial gradient [ ] (A/m2), and both must be known at the vessel
location to compute the magnetic force (see [11] and Supplementary Figure 1
[www.futuremedicine.com/doi/suppl/10.2217/nnm.10.104]). In Equation 3,  is the
equilibrium velocity (m/s) of the nanoparticle created by the applied magnetic force. To
compute Ψ, as well as D, DT and Pe, all variables should be stated in SI units (e.g., as a =
10−7 m for a 100 nm radius particle, then all units will exactly cancel, yielding the four
nondimensional numbers; see the detailed instructions in the supplementary material and in
[11]). As the magnetic-Richardson number increases beyond 1, the magnetic force exceeds
the blood drag force at the vessel centerline. Thus, the Richardson number is a key indicator
of the success of magnetic drug focusing, but, as noted previously, magnetic focusing can
occur even if this number is substantially below 1 (as in the rat example).
The second key number that determines the success of magnetic drug delivery is the mass
Péclet number [12]. It quantifies the competition between particle movement (convection)
by blood flow versus particle diffusion in the blood, and is defined as:
(4)
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Here, DTot (in m2/s) takes into account the scattering of nanoparticles by collisions with
blood cells, an effect that can be modeled as additional diffusion [10]. For 250 nm diameter
particles in rat capillaries, Pe ≈ 1000, meaning nanoparticles are convected much faster than
they diffuse.
Finally, the Renkin-reduced diffusion coefficients [9], for the endothelium membrane and
the surrounding tissue, are defined as:
(5)
(6)
where DB is the particle diffusion in blood caused by thermal fluctuations, DS is the
additional diffusion caused by collision with blood cells, DM is the diffusion in the
endothelial membrane (it is set to zero if there is no extravasation), and DT is the particle
diffusion in surrounding tissue (all in units m2/s). As an example, for 250 nm diameter
particles, leaky tumor rat capillaries with fenestrations on the order of 600 nm have a
membrane Renkin coefficient of D ≈ 0.36; for a tumor extracellular spacing of 1 μm, the
tissue Renkin coefficient is DT ≈ 0.56 [9].
Under physiological conditions, for vessel diameters and blood velocities ranging from dB=
6 μm and VBmax= 0.1 mm/s (rat capillaries) to dB = 3 cm and VBmax = 40 cm/s (human
aorta), and for achievable physical parameters, particle diameters ranging from 1 nm to 5
μm, and magnet field strengths no greater than 4 Tesla (MRI strengths), the four
nondimensional parameters can range between 4 × 10−18 ≤ Ψ ≤ 6 × 103, 1 ≤ Pe ≤ 1 × 1012,
and 0 ≤ min(D, DT) ≤ 1 (it suffices to consider the minimum of the two Renkin coefficients,
as the smaller coefficient determines the behavior). To map nanoparticle behaviors across
this entire parameter space, we first divided our nondimensional number space (i.e.,
Richardson, Péclet and Renkin) into a coarse 7 × 7 × 5 grid, and carried out a simulation of
particle behavior at each number triplet (a total of 245 simulations). This revealed the three
types of behaviors shown in Figure 3 and discussed next. To identify more precisely the
boundaries between these three behavior types, we carried out 475 further simulations on a
finer grid, which spanned the transitions from one type of behavior to another.
For each Richardson–Péclet–Renkin triplet, we evaluated the transient and final
concentration of nanoparticles, in the blood, endothelial membrane and surrounding tissue,
according to EQUATIONS 1 & 2. Initially, this was done using the commercial multiphysics
package COMSOL [101], a package that has been used fairly commonly in the magnetic
drug delivery literature for its ability to couple partial differential equations. In the
numerical methods community, it is well known that high Péclet number cases are
extremely difficult to solve; COMSOL failed to solve cases for Pe values greater than 1300.
To achieve the solutions for Pe numbers as high as 1012, we developed and implemented a
sophisticated inhouse numerical method. Our resulting vessel–membrane–tissue (VMT)
solver for the partial differential Equations 1 & 2 is based on a combination of the
following four techniques:
▪ Factorization of the differential operator as a product of 1D differential operators and
efficient solution of the corresponding ordinary differential equations at every time step
(the ADI method [13]);
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▪ Use of a graded mesh in the vessel domain;
▪ Use of changes of unknowns that transform the spatial operators in the membrane and
tissue domains into operators of Helmholtz type, which enables the use of highly
optimized steady-state solvers;
▪ An on-and-off fluid-freezing methodology designed to effectively resolve the large
time-scale separation between the dynamics in the blood domain and the much slower
diffusion processes in the membrane and tissue.
The details underlying the VMT solver can be found in [11], and a future contribution in [BENI
ET AL., MANUSCRIPT IN PREPARATION]. The VMT solver was both more accurate and 500 times faster than
COMSOL, and it was able to solve cases that COMSOL could not. Our recent work shows
that significant further improvements of the algorithm are feasible [BENI ET AL., MANUSCRIPT IN
PREPARATION].
The VMT simulations predicted nanoparticle behavior for any scenario within the
considered range of physiological/feasible circumstances. For any blood vessel, at any body
depth, with any diameter, and blood flow velocity, for nanoparticles of any size and material
properties under any applied magnetic field, there is a corresponding nondimensional
number triplet (Richardson–Péclet–Renkin), given by Equations 3-6, which uniquely
determines nanoparticle behavior in and around that blood vessel. By looking up the
behavior of that triplet on our grid of 720 conducted simulations, we predicted the type of
behavior (FIGURES 3 & 4), and compared it against available in vitro and in vivo magnetic drug
delivery experiments. We found excellent agreement (Figure 5) and were able to explain
observed behavior that was not previously understood.
Results & discussion
Magnetic nanoparticles travel through the blood and into the surrounding tissue under three
competing effects: under blood convection, diffusion (including both extravasation and
scattering by blood cells [9,10]), and from the pull of the applied magnetic fields. The
Richardson, Péclet, and Renkin numbers quantify the competition between these three
effects (EQUATIONS 3-6).
Our simulations revealed the three types of behavior shown in Figure 3. In the velocity-
dominated case, the created magnetic forces are weak compared with the blood flow forces,
so they cannot capture the particles and, therefore, the nanoparticles are washed out the back
of the blood vessel. In the magnetic-dominated case, the magnetic forces far exceed the
ability of the vessel membrane and tissue to resist particle motion, to the point where the
particles are pulled by the magnet out of the vessel and, eventually, also out of the region of
tissue being considered. This case either requires exceedingly strong magnetic forces, or a
blood vessel membrane that does not substantially inhibit particle movement (e.g., a
sufficiently ‘leaky’ tumor vessel). In the boundary-layer case, nanoparticles accumulate in a
layer at the vessel wall and, if extravasation is possible, are then in the correct location to
enter the surrounding tissue. It is this last case that is most interesting and effective for drug
delivery, as the applied magnetic field serves to concentrate the therapeutic.
To understand which behaviors occur, and when, we first show a case for a fixed Péclet
number of Pe = 1000 (Figure 4), as corresponds to our previous rat capillary example. For
each (Richardson–Renkin) pair, it shows which behavior is occurring. The behavior
switches from velocity-dominated to boundary-layer cases as the Richardson number
increases, but, as seen from the plot, and described earlier, this transition can happen well
before the magnetic forces attain the value of blood drag forces at the vessel centerline. For
Pe = 1000, the boundary-layer behavior begins when Ψ exceeds 5 × 10−5 (i.e., when the
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magnetic forces have reached just 0.005% of the centerline drag forces). The transition from
the velocity to boundary-layer behavior is gradual, so we show the delineation between them
as a ‘fuzzy’ border. This transition is delayed as the Renkin number increases (the angled
border at the top of the plot) because, if diffusion in the endothelium and tissue is high, any
build-up of particles in the tissue can diffuse more easily back out into the vessel, and then
be swept away by blood flow. For the rat capillary example, Figure 4 allows us to read how
much magnetic force is necessary to achieve magnetic focusing – from the log scale, the
magnetic force applied should be greater than 0.005% of the centerline blood drag force.
The work flow for utilizing the predictive capabilities of this method is outlined in
Supplementary Figure 1 (www.futuremedicine.com/doi/suppl/10.2217/nnm.10.104).
Initially, the researcher should determine the variables involved in the experiment. Then
they should calculate the parameters necessary for determining the nondimensional numbers
using the equations provided. Finally, knowing the nondimensional numbers associated with
the experiment enables the researcher to predict the nanoparticle behavior within the specific
experimental set-up.
Figure 5 provides the dependence on all three nondimensional numbers, as well as a
comparison against the five available prior in vitro and in vivo experimental studies of
magnetic focusing. Each study had a range of nondimensional numbers associated with it. In
vitro studies typically had a small range, owing to tightly controlled experimental
conditions. In vivo studies had a larger spread, since a range of organism parameters must be
considered, encompassing small and large, shallow and deep blood vessels with a wide
physiological range of blood flow velocities. Based on this, shapes could be drawn that
outline the range of parameters in each animal or human experiment (details in [11]). Figure
5 shows the ranges for each study against our predicted behaviors. In all cases, we found
that, when magnetic focusing was observed (or not), in the in vitro cases, or to certain depths
for slow or fast blood flows in the human and animal experiments, it matched our
predictions. We were able to correctly predict both the occurrence and amount of magnetic
capture in in vitro experiments (even in a case where the standard force comparison failed,
thus resolving an open question noted by the authors [14]). For in vivo experiments we
correctly predicted observed particle accumulation in rats [5,15], as well as the depth of
focusing (~5 cm) in a human head-and-neck tumor (as was measured by MRI after the
treatment) [1]. Thus, our analysis provides an accurate way of predicting behavior across the
range of physiological and expected engineering parameters and, as such, it should be a
valuable tool for the design of next-generation magnetic drug delivery systems.
Future perspective
Magnetic drug delivery is emerging as a powerful drug-targeting option, with the ability to
physically direct therapeutics to sites of disease [1,4,6]. The design of effective magnetic
drug delivery systems is an endeavor that must match engineering to physiology and, as
such, it requires an ability to understand and predict how engineering choices (e.g., particle
size and composition, magnet placement, shape and strength) affect drug distribution in vivo.
This cannot be achieved through animal experiments alone – the number of animals that
would be required to exhaustively search the design space is staggering – and current simple
back-of-the-envelope analyses have proved insufficient. Thus, there is a broad need for the
type of modeling conducted by our group. Although physiological behavior is complex, and
predicting it is a great challenge, our current analysis is a sensible next step – it uses
physical first principles and available physiological information, and is effective. Weak
points of the modeling must now be identified, such as our simple treatment of extravasation
as diffusion [9], and should be rank ordered (to assess which weaknesses should be
addressed first to improve the predictions and enable better design of next-generation
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magnetic drug delivery systems) and, then, in vitro and animal experiments must be devised
to isolate, understand, measure and fix the weaknesses. For example, we are currently
creating experiments to precisely measure particle transport through excised tissue and
blood vessel walls under carefully applied magnetic forces to quantify diffusion and
extravasation. The suite of tools that we will build will teach us a great deal about the
behavior of nano-particles in vivo, and will enable better design and optimization of next-
generation magnetic drug delivery systems.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Rat experiments
(A) The 0.5 T magnet and (B) concentrated ferrofluid is visible under the skin after
treatment [15].
Figure adapted with permission from C Bergemann (Chemicell, Berlin, Germany) and A
Lübbe (Medical Center for Health, Bad Lippspringe, Germany).
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Figure 2. Simulation domain
(A) Magnetic drug focusing in Phase I human clinical trials [1].
(B) We consider a single blood vessel (of any size, depth and blood velocity) and
surrounding tissue and analyze the spatial distribution of magnetic particles.
(A) Adapted with permission from A Lübbe (Medical Center for Health, Bad Lippspringe,
Germany).
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Figure 3. The three behaviors
(A) Velocity dominated, (B) magnetic dominated and (C) a boundary layer formation. In
each of the three panels, the top, middle and bottom layers show a cross-section through the
blood vessel, endothelial layer and surrounding tissue, respectively; the equilibrium
distribution of nanoparticles is shown by the coloring (white = low; black = high; but case
(C) is shown in a log scale); and the blue curve on the right shows the concentration of
nanoparticles at the dotted black line location. Both the velocity and magnetic dominated
case have a nearly uniform nanoparticle concentration (note the zoomed in 0.99 to 1.01
concentration scale for cases [A & B] versus the log scale for case [C]). The focusing
magnet is located at the bottom and pulls nanoparticles towards it. Only in the boundary
layer case does a distinct concentration build-up occur and the concentration within the
tissue exceeds that of the blood vessel. The velocity dominated case does not easily allow
particles to enter the tissue due to the constant movement of particles out of the blood vessel.
The magnetic dominated case allows particles to enter the vessel membrane and tissue space
but does not concentrate them within the vessel membrane or tissue. Only the boundary
layer case enables particles to significantly concentrate within the vessel membrane and
tissue space.
See [11] for more details.
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Figure 4. The behavior of nanoparticles for varying richardson and renkin numbers at a fixed
Péclet number (corresponding to the rat capillary example)
The three behavior domains are shown: velocity dominated on the left, boundary layer on
the right (with a continuous transition region between them) and a strip of magnetic
dominated cases at the top for Renkin numbers near unity. For any Richardson and Renkin
pair, the predicted nanoparticle behavior is determined by looking up that (Richardson,
Renkin) point on the graph and seeing which region it falls into. Note that the minimum of
the endothelium and tissue Renkin numbers determines the type of behavior and so it is this
quantity that is used on the vertical axis. The rat capillary example is marked by the green
circle.
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Figure 5. The experimental domains of prior studies plotted on a 3d representation of the
nondimensional number space versus our predictions
The shaded regions show the three behavior types: magnetic dominated against the back in
blue; velocity dominated at the bottom left (the curved green ramp shape); and boundary
layer formation everywhere else (in white). The in vitro experiments are shown as small
boxes [14,16]; the in vivo experiments are shown as large colored wireframes (the two boxes
and the extruded curved triangle) [1,5,15]. Regions where the experiments leave the
boundary layer formation region and enter the velocity dominated region are denoted by
translucent shading (seen in the Lübbe, Widder and Bergemann cases, Ganguly and Xu
remain wholly in the boundary layer domain). The outlined shapes cover the range of cases
expected in the experiments. In all cases, the observed absence or presence of magnetic drug
focusing matched our theoretical predictions. All of these experiments were designed to be
successful and they all largely lie in the boundary build-up domain, although for Lübbe [1]
there are deeper vessels with faster blood flows which fall into the velocity dominated case.
Our analysis correctly predicted when those situations occurred.
See [11] for a more detailed version of this figure.
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